CI vs. ILMN: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at CI and ILMN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | CI | ILMN |
|---|---|---|
| Company Name | The Cigna Group | Illumina, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Providers & Services | Life Sciences Tools & Services |
| Market Capitalization | 72.67 billion USD | 18.59 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | March 31, 1982 | July 28, 2000 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of CI and ILMN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | CI | ILMN |
|---|---|---|
| 5-Day Price Return | 4.45% | -2.06% |
| 13-Week Price Return | -9.16% | 19.45% |
| 26-Week Price Return | -10.68% | 53.54% |
| 52-Week Price Return | -18.79% | -15.58% |
| Month-to-Date Return | 10.33% | -2.80% |
| Year-to-Date Return | -2.35% | -10.14% |
| 10-Day Avg. Volume | 3.12M | 1.75M |
| 3-Month Avg. Volume | 1.91M | 1.81M |
| 3-Month Volatility | 44.35% | 63.15% |
| Beta | 0.25 | 1.41 |
Profitability
Return on Equity (TTM)
CI
15.06%
Health Care Providers & Services Industry
- Max
- 24.67%
- Q3
- 15.54%
- Median
- 8.37%
- Q1
- 5.49%
- Min
- -2.09%
CI’s Return on Equity of 15.06% is on par with the norm for the Health Care Providers & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
ILMN
29.98%
Life Sciences Tools & Services Industry
- Max
- 23.81%
- Q3
- 11.79%
- Median
- 7.51%
- Q1
- 3.14%
- Min
- -6.95%
ILMN’s Return on Equity of 29.98% is exceptionally high, placing it well beyond the typical range for the Life Sciences Tools & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Net Profit Margin (TTM)
CI
2.29%
Health Care Providers & Services Industry
- Max
- 9.33%
- Q3
- 4.80%
- Median
- 2.90%
- Q1
- 0.93%
- Min
- -3.28%
CI’s Net Profit Margin of 2.29% is aligned with the median group of its peers in the Health Care Providers & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
ILMN
16.39%
Life Sciences Tools & Services Industry
- Max
- 33.77%
- Q3
- 17.97%
- Median
- 8.97%
- Q1
- 3.80%
- Min
- -11.89%
ILMN’s Net Profit Margin of 16.39% is aligned with the median group of its peers in the Life Sciences Tools & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
CI
3.45%
Health Care Providers & Services Industry
- Max
- 18.35%
- Q3
- 8.71%
- Median
- 5.10%
- Q1
- 2.10%
- Min
- -3.07%
CI’s Operating Profit Margin of 3.45% is around the midpoint for the Health Care Providers & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
ILMN
18.07%
Life Sciences Tools & Services Industry
- Max
- 31.55%
- Q3
- 21.26%
- Median
- 14.06%
- Q1
- 8.54%
- Min
- 0.11%
ILMN’s Operating Profit Margin of 18.07% is around the midpoint for the Life Sciences Tools & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | CI | ILMN |
|---|---|---|
| Return on Equity (TTM) | 15.06% | 29.98% |
| Return on Assets (TTM) | 3.99% | 11.36% |
| Net Profit Margin (TTM) | 2.29% | 16.39% |
| Operating Profit Margin (TTM) | 3.45% | 18.07% |
| Gross Profit Margin (TTM) | 9.55% | 66.74% |
Financial Strength
Current Ratio (MRQ)
CI
0.83
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.56
- Median
- 1.28
- Q1
- 0.92
- Min
- 0.01
CI’s Current Ratio of 0.83 falls into the lower quartile for the Health Care Providers & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
ILMN
1.43
Life Sciences Tools & Services Industry
- Max
- 4.76
- Q3
- 2.87
- Median
- 1.75
- Q1
- 1.37
- Min
- 0.57
ILMN’s Current Ratio of 1.43 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
CI
0.81
Health Care Providers & Services Industry
- Max
- 2.41
- Q3
- 1.39
- Median
- 0.74
- Q1
- 0.46
- Min
- 0.00
CI’s Debt-to-Equity Ratio of 0.81 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
ILMN
0.84
Life Sciences Tools & Services Industry
- Max
- 0.95
- Q3
- 0.70
- Median
- 0.45
- Q1
- 0.18
- Min
- 0.00
ILMN’s leverage is in the upper quartile of the Life Sciences Tools & Services industry, with a Debt-to-Equity Ratio of 0.84. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
CI
2.32
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.46
- Median
- 4.52
- Q1
- 2.04
- Min
- -4.44
CI’s Interest Coverage Ratio of 2.32 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.
ILMN
-2.28
Life Sciences Tools & Services Industry
- Max
- 45.00
- Q3
- 27.84
- Median
- 7.16
- Q1
- 2.12
- Min
- -14.08
ILMN has a negative Interest Coverage Ratio of -2.28. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | CI | ILMN |
|---|---|---|
| Current Ratio (MRQ) | 0.83 | 1.43 |
| Quick Ratio (MRQ) | 0.73 | 1.03 |
| Debt-to-Equity Ratio (MRQ) | 0.81 | 0.84 |
| Interest Coverage Ratio (TTM) | 2.32 | -2.28 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
CI
2.22%
Health Care Providers & Services Industry
- Max
- 5.51%
- Q3
- 2.66%
- Median
- 1.06%
- Q1
- 0.00%
- Min
- 0.00%
CI’s Dividend Yield of 2.22% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.
ILMN
0.00%
Life Sciences Tools & Services Industry
- Max
- 1.02%
- Q3
- 0.67%
- Median
- 0.32%
- Q1
- 0.00%
- Min
- 0.00%
ILMN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
CI
26.01%
Health Care Providers & Services Industry
- Max
- 187.56%
- Q3
- 81.14%
- Median
- 33.42%
- Q1
- 0.00%
- Min
- 0.00%
CI’s Dividend Payout Ratio of 26.01% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
ILMN
0.00%
Life Sciences Tools & Services Industry
- Max
- 97.67%
- Q3
- 61.34%
- Median
- 18.53%
- Q1
- 0.00%
- Min
- 0.00%
ILMN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | CI | ILMN |
|---|---|---|
| Dividend Yield (TTM) | 2.22% | 0.00% |
| Dividend Payout Ratio (TTM) | 26.01% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
CI
11.72
Health Care Providers & Services Industry
- Max
- 48.86
- Q3
- 32.22
- Median
- 21.78
- Q1
- 13.97
- Min
- 8.01
In the lower quartile for the Health Care Providers & Services industry, CI’s P/E Ratio of 11.72 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
ILMN
26.23
Life Sciences Tools & Services Industry
- Max
- 78.22
- Q3
- 57.42
- Median
- 34.18
- Q1
- 28.39
- Min
- 1.55
In the lower quartile for the Life Sciences Tools & Services industry, ILMN’s P/E Ratio of 26.23 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
CI
0.27
Health Care Providers & Services Industry
- Max
- 3.66
- Q3
- 1.64
- Median
- 0.72
- Q1
- 0.27
- Min
- 0.10
In the lower quartile for the Health Care Providers & Services industry, CI’s P/S Ratio of 0.27 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
ILMN
4.30
Life Sciences Tools & Services Industry
- Max
- 10.69
- Q3
- 6.37
- Median
- 4.95
- Q1
- 3.27
- Min
- 1.04
ILMN’s P/S Ratio of 4.30 aligns with the market consensus for the Life Sciences Tools & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
CI
1.84
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.33
- Median
- 2.48
- Q1
- 1.31
- Min
- 0.65
CI’s P/B Ratio of 1.84 is within the conventional range for the Health Care Providers & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
ILMN
5.93
Life Sciences Tools & Services Industry
- Max
- 8.12
- Q3
- 5.04
- Median
- 3.94
- Q1
- 2.12
- Min
- 1.13
ILMN’s P/B Ratio of 5.93 is in the upper tier for the Life Sciences Tools & Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | CI | ILMN |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 11.72 | 26.23 |
| Price-to-Sales Ratio (TTM) | 0.27 | 4.30 |
| Price-to-Book Ratio (MRQ) | 1.84 | 5.93 |
| Price-to-Free Cash Flow Ratio (TTM) | 7.50 | 18.44 |